ATAD3B

Summary

ATAD3B (ATPase family AAA domain containing 3B, HGNC:24007) is a protein-coding gene on chromosome 1p36.33, encoding ATPase family AAA domain-containing protein 3B (Q5T9A4). May play a role in a mitochondrial network organization typical for stem cells, characterized by reduced mitochondrial metabolism, low mtDNA copies and fragmentated mitochondrial network.

The protein encoded by this gene is localized to the mitochondrial inner membrane, where it can bind to a highly-related protein, ATAD3A. ATAD3A appears to interact with matrix nucleoid complexes, and the encoded protein negatively regulates that interaction. This gene is expressed almost exclusively in pluripotent embryonic stem cells and some cancer cells. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 83858 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 257 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_031921

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24007
Approved symbol	ATAD3B
Name	ATPase family AAA domain containing 3B
Location	1p36.33
Locus type	gene with protein product
Status	Approved
Aliases	TOB3, KIAA1273
Ensembl gene	ENSG00000160072
Ensembl biotype	protein_coding
OMIM	612317
Entrez	83858

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000308647, ENST00000378736, ENST00000472194, ENST00000474481, ENST00000485748, ENST00000673477, ENST00000940533, ENST00000940534, ENST00000940535, ENST00000940536

RefSeq mRNA: 2 — MANE Select: NM_031921 NM_001317238, NM_031921

CCDS: CCDS30

Canonical transcript exons

ENST00000673477 — 16 exons

Exon	Start	End
ENSE00003459370	1485016	1485171
ENSE00003467707	1477274	1477350
ENSE00003474888	1480867	1480936
ENSE00003497242	1490563	1490671
ENSE00003505365	1490257	1490424
ENSE00003510521	1482545	1482614
ENSE00003569130	1478644	1478745
ENSE00003594545	1486110	1486235
ENSE00003608502	1479049	1479108
ENSE00003654064	1482138	1482303
ENSE00003655926	1485782	1485838
ENSE00003670332	1489204	1489274
ENSE00003689846	1487863	1487914
ENSE00003889014	1471765	1472089
ENSE00003892109	1486544	1486668
ENSE00003892597	1495485	1497848

Expression profiles

Bgee: expression breadth ubiquitous, 248 present calls, max score 92.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.1003 / max 271.0313, expressed in 1794 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
116	20.0355	1794
117	0.0649	14

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	92.83	gold quality
sural nerve	UBERON:0015488	92.61	gold quality
metanephros cortex	UBERON:0010533	92.56	gold quality
lower esophagus mucosa	UBERON:0035834	91.93	gold quality
mucosa of transverse colon	UBERON:0004991	91.91	gold quality
pituitary gland	UBERON:0000007	91.61	gold quality
granulocyte	CL:0000094	91.50	gold quality
right lobe of thyroid gland	UBERON:0001119	91.48	gold quality
ileal mucosa	UBERON:0000331	91.42	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.93	gold quality
skin of leg	UBERON:0001511	90.68	gold quality
left ovary	UBERON:0002119	90.32	gold quality
left lobe of thyroid gland	UBERON:0001120	90.29	gold quality
skin of abdomen	UBERON:0001416	90.28	gold quality
cerebellar hemisphere	UBERON:0002245	90.06	gold quality
endocervix	UBERON:0000458	89.96	gold quality
cerebellar cortex	UBERON:0002129	89.95	gold quality
body of pancreas	UBERON:0001150	89.94	gold quality
left uterine tube	UBERON:0001303	89.93	gold quality
upper arm skin	UBERON:0004263	89.75	silver quality
esophagus mucosa	UBERON:0002469	89.58	gold quality
minor salivary gland	UBERON:0001830	89.52	gold quality
body of uterus	UBERON:0009853	89.47	gold quality
spleen	UBERON:0002106	89.45	gold quality
transverse colon	UBERON:0001157	89.36	gold quality
right lobe of liver	UBERON:0001114	89.26	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.19	gold quality
apex of heart	UBERON:0002098	89.18	gold quality
thyroid gland	UBERON:0002046	89.14	gold quality
upper lobe of left lung	UBERON:0008952	89.11	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6819	yes	263.76
E-ANND-3	no	3.33

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1, MYC

miRNA regulators (miRDB)

8 targeting ATAD3B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-4286	97.20	64.37	1587
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-365A-5P	94.91	63.72	471
HSA-MIR-365B-5P	94.91	63.79	470

Literature-anchored findings (GeneRIF, showing 11)

• Results suggest that mitochondrial DNA displacement loops serve to recruit ATAD3 protein for the purpose of forming or segregating mitochondrial nucleoids. (PMID:17210950)
• These results demonstrate the potential for ATAD 3B as a putative marker in discriminating astrocytomas from oligodendrogliomas. (PMID:18639545)
• ATAD3 may therefore be implicated in an unknown but essential and growth-linked mitochondrial function existing since pluri-cellular -organization and involved in tumorigenesis. (PMID:22192748)
• ATAD3B is a negative regulator of ATAD3A and may function as an adaptor of mitochondrial homeostasis and metabolism in human pluripotent embryonic stem cells and cancer cells. (PMID:22664726)
• results indicated the ATAD3B gene, which does not have ERalpha binding site within 20 kb of its TSS, to be significantly associated with poor patient survival. (PMID:23818839)
• exploring ATAD3 mRNA expression, we confirmed the existence of an alternative splicing in rodent and of several mRNA isoforms in human (PMID:24239551)
• ATAD3B region deletions cause cerebellar dysfunction associated with altered mitochondrial DNA and cholesterol metabolism. (PMID:28549128)
• AAA-TOB3 was highly expressed in lung adenocarcinoma, and the up-regulation of AAA-TOB3 correlated with lymph node metastasis and advanced stage of lung adenocarcinoma. (PMID:28623644)
• ATAD3B is a mitophagy receptor mediating clearance of oxidative stress-induced damaged mitochondrial DNA. (PMID:33665835)
• ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study. (PMID:35136033)
• Circ_ATAD3B inhibits cell proliferation of breast cancer via mediating the miR-570-3p/MX2 axis. (PMID:37286092)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio	atad3	ENSDARG00000086848

Paralogs (2): ATAD3A (ENSG00000197785), ATAD3C (ENSG00000215915)

Protein

Protein identifiers

ATPase family AAA domain-containing protein 3B — Q5T9A4 (reviewed: Q5T9A4)

Alternative names: AAA-TOB3

All UniProt accessions (2): Q5T9A4, A0A5K1VW56

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in a mitochondrial network organization typical for stem cells, characterized by reduced mitochondrial metabolism, low mtDNA copies and fragmentated mitochondrial network. May act by suppressing ATAD3A function, interfering with ATAD3A interaction with matrix nucleoid complexes.

Subunit / interactions. Forms heterooligomers with ATAD3A. Interacts with components of the mitochondrial ribosome, including MRPL11 and MRPS18B, and with other proteins involved in mitochondrial RNA metabolism, possibly via interaction with ATAD3A. Interacts with GADD45GIP1.

Subcellular location. Mitochondrion inner membrane.

Tissue specificity. Tends to be down-regulated in differentiated cells and re-expressed in pluripotent stem cells or cancer cells (at protein level).

Induction. Up-regulated by MYC.

Similarity. Belongs to the AAA ATPase family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5T9A4-1	1, AAA-TOB3l	yes
Q5T9A4-2	2
Q5T9A4-3	3, AAA-TOB3s

RefSeq proteins (2): NP_001304167, NP_114127* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003593	AAA+_ATPase	Domain
IPR003959	ATPase_AAA_core	Domain
IPR021911	ATAD3_N	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00004, PF12037

UniProt features (24 total): splice variant 6, compositionally biased region 3, modified residue 3, topological domain 2, sequence conflict 2, region of interest 2, initiator methionine 1, chain 1, binding site 1, sequence variant 1, intramembrane region 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T9A4-F1	77.69	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 352–359

Post-translational modifications (3): 2, 427, 495

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 54 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, TGCGCANK_UNKNOWN, GOCC_SECRETORY_GRANULE, MYCMAX_01, GOCC_MITOCHONDRIAL_ENVELOPE, FISCHER_DREAM_TARGETS, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, GOCC_SECRETORY_VESICLE, GOCC_ORGANELLE_INNER_MEMBRANE, GOCC_SECRETORY_GRANULE_MEMBRANE, USF2_Q6, MYC_Q2, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, GOMF_ATP_HYDROLYSIS_ACTIVITY, GOMF_ADENYL_NUCLEOTIDE_BINDING

GO Biological Process (1): mitochondrion organization (GO:0007005)

GO Molecular Function (3): ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166)

GO Cellular Component (6): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), plasma membrane (GO:0005886), secretory granule membrane (GO:0030667), ficolin-1-rich granule membrane (GO:0101003), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Innate Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
organelle organization	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
ATP-dependent activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
membrane	1
cell periphery	1
secretory granule	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
secretory granule membrane	1
tertiary granule	1
ficolin-1-rich granule	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1202 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATAD3B	TOB2	Q14106	572
ATAD3B	RAD51	Q06609	544
ATAD3B	MYO5C	Q9NQX4	433
ATAD3B	PRAMEF18	Q5VWM3	432
ATAD3B	TOB1	P50616	417
ATAD3B	PRAMEF7	Q5VXH5	417
ATAD3B	ABCB7	O75027	409
ATAD3B	DUT	P33316	406
ATAD3B	TGM3	Q08188	404
ATAD3B	CITED1	Q99966	393
ATAD3B	SYNE2	Q8WXH0	390
ATAD3B	MRTFA	Q969V6	381
ATAD3B	DNAH5	Q8TE73	378
ATAD3B	MCM6	Q14566	372
ATAD3B	MYC	P01106	367

IntAct

177 interactions, top by confidence:

A	B	Type	Score
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
MED18	MED19	psi-mi:“MI:0914”(association)	0.840
MED7	MED19	psi-mi:“MI:0914”(association)	0.840
NDUFAF1	NDUFS3	psi-mi:“MI:0914”(association)	0.790
NDUFAF4	NDUFS7	psi-mi:“MI:0914”(association)	0.790
PRELID3B	TRIAP1	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
BRAF	KRAS	psi-mi:“MI:0914”(association)	0.680
PKN3	ARHGAP10	psi-mi:“MI:0914”(association)	0.680
DYRK1A	RB1	psi-mi:“MI:0914”(association)	0.670
LYRM7	NDUFAB1	psi-mi:“MI:0914”(association)	0.640
NDUFAF4	NDUFS8	psi-mi:“MI:0914”(association)	0.640
ETFRF1	NDUFAB1	psi-mi:“MI:0914”(association)	0.640
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
ATAD3A	HSPD1	psi-mi:“MI:0914”(association)	0.580
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
KSR2	POLR3A	psi-mi:“MI:0914”(association)	0.530
MAPK6	ECI2	psi-mi:“MI:0914”(association)	0.530
EGFR	NDUFA4	psi-mi:“MI:0914”(association)	0.530
CLEC11A	VWA8	psi-mi:“MI:0914”(association)	0.530
ZNRD2	MYO9A	psi-mi:“MI:0914”(association)	0.530
PBXIP1	KCNN4	psi-mi:“MI:0914”(association)	0.530
DYRK1B	BMAL1	psi-mi:“MI:0914”(association)	0.530
ATAD3B	HSPD1	psi-mi:“MI:0914”(association)	0.480
vpu	SCAMP3	psi-mi:“MI:0914”(association)	0.460

BioGRID (300): ATAD3B (Affinity Capture-MS), ATAD3B (Affinity Capture-MS), ATAD3B (Co-fractionation), ATAD3B (Co-fractionation), ATAD3B (Co-fractionation), ATAD3B (Co-fractionation), EIF2S2 (Co-fractionation), FTSJ3 (Co-fractionation), PHB2 (Co-fractionation), RPN1 (Co-fractionation), SRP68 (Co-fractionation), SSR1 (Co-fractionation), VCP (Co-fractionation), ATAD3B (Affinity Capture-MS), ATAD3B (Affinity Capture-MS)

ESM2 similar proteins: A0JWY3, A4H452, A4HSC9, A4WYU7, A8NS89, A9WSI4, B8NHD6, B8ZRF0, C0ZZV2, C6WIC8, C8XAR0, F4IF36, O15706, O50202, O96553, P0DV51, P17255, P23225, P34118, P46509, P53904, P54659, P84193, Q0JKD0, Q14764, Q2UMG1, Q3KRE0, Q3SYU9, Q4CUM2, Q4QJJ7, Q54WZ2, Q54WZ3, Q57Z03, Q5EAJ7, Q5R9N2, Q5T9A4, Q5ZMI4, Q62667, Q69RJ0, Q6P3L0

Diamond homologs: A7YWC4, C8W731, D1C4U5, D5H7Z5, O27092, P42811, Q20748, Q3KRE0, Q58889, Q58E76, Q5T2N8, Q5T9A4, Q6NVR9, Q6PAX2, Q925I1, Q9NVI7, Q9VEX6, A7I8B8, B3DV46, C7N914, D7Y2H4, O26824, O64982, P03974, P0DKJ9, P0DKK0, P23787, P25694, P32795, P46462, P54811, P54812, P55072, P73437, Q01853, Q01939, Q05AS3, Q2NIN5, Q3ULF4, Q3UMC0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 210 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ERBB2 ECD mutants	5	24.3×	2e-04
GRB2 events in ERBB2 signaling	5	23.0×	2e-04
SHC1 events in ERBB2 signaling	5	17.2×	5e-04
Signaling by ERBB2 TMD/JMD mutants	5	17.2×	5e-04
Signaling by ERBB2 KD Mutants	5	15.3×	7e-04
Signaling by high-kinase activity BRAF mutants	5	11.5×	2e-03
Complex I biogenesis	9	10.8×	5e-05
MAP2K and MAPK activation	5	10.3×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
mitochondrial respiratory chain complex I assembly	8	17.5×	2e-05
peptidyl-tyrosine phosphorylation	7	15.7×	1e-04
mitochondrial electron transport, NADH to ubiquinone	6	11.4×	3e-03
intrinsic apoptotic signaling pathway	6	11.4×	3e-03
protein autophosphorylation	8	6.2×	9e-03
protein phosphorylation	15	5.4×	8e-05
negative regulation of apoptotic process	17	3.1×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

257 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	193
Likely benign	17
Benign	8

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
144807	GRCh38/hg38 1p36.33-36.32(chr1:1118636-4179080)x1	Pathogenic

SpliceAI

2886 predictions. Top by Δscore:

Variant	Effect	Δscore
1:1472085:CTCGC:C	donor_gain	1.0000
1:1472086:TCGC:T	donor_gain	1.0000
1:1472087:CGCG:C	donor_loss	1.0000
1:1472088:GC:G	donor_gain	1.0000
1:1472089:CGTG:C	donor_loss	1.0000
1:1472090:G:GG	donor_gain	1.0000
1:1472090:GT:G	donor_loss	1.0000
1:1477351:G:GG	donor_gain	1.0000
1:1478743:GCC:G	donor_gain	1.0000
1:1478746:G:GG	donor_gain	1.0000
1:1479048:GA:G	acceptor_gain	1.0000
1:1479105:GCAG:G	donor_gain	1.0000
1:1479106:CAGG:C	donor_loss	1.0000
1:1479107:AGGTG:A	donor_loss	1.0000
1:1479109:G:C	donor_loss	1.0000
1:1480851:T:TA	acceptor_gain	1.0000
1:1480853:C:CA	acceptor_gain	1.0000
1:1480854:G:A	acceptor_gain	1.0000
1:1480865:A:AG	acceptor_gain	1.0000
1:1480866:G:GA	acceptor_gain	1.0000
1:1480866:GC:G	acceptor_gain	1.0000
1:1480866:GCA:G	acceptor_gain	1.0000
1:1480921:G:GT	donor_gain	1.0000
1:1480932:GCGAG:G	donor_gain	1.0000
1:1480933:CGAGG:C	donor_loss	1.0000
1:1480936:GGT:G	donor_loss	1.0000
1:1480937:G:GA	donor_loss	1.0000
1:1480938:T:A	donor_loss	1.0000
1:1482130:T:TA	acceptor_gain	1.0000
1:1482131:G:A	acceptor_gain	1.0000

AlphaMissense

4189 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:1472065:G:C	A61P	0.994
1:1472032:T:C	F50L	0.993
1:1472034:C:A	F50L	0.993
1:1472034:C:G	F50L	0.993
1:1472060:C:A	A59D	0.993
1:1472057:C:A	A58D	0.992
1:1472059:G:C	A59P	0.989
1:1479052:G:C	A130P	0.989
1:1472068:G:C	A62P	0.988
1:1472033:T:G	F50C	0.987
1:1472054:G:C	R57P	0.987
1:1478653:G:C	A98P	0.987
1:1472056:G:C	A58P	0.986
1:1472048:T:C	L55P	0.984
1:1472052:G:C	E56D	0.982
1:1472052:G:T	E56D	0.982
1:1472053:C:A	R57S	0.982
1:1479077:G:C	R138P	0.982
1:1472048:T:A	L55Q	0.981
1:1472078:T:C	L65P	0.981
1:1472036:A:G	D51G	0.979
1:1472033:T:C	F50S	0.978
1:1472072:G:C	R63P	0.978
1:1477298:T:C	L77P	0.978
1:1472069:C:A	A62E	0.977
1:1479073:G:C	A137P	0.977
1:1479083:G:C	R140P	0.975
1:1477288:G:C	A74P	0.972
1:1472045:G:A	G54D	0.970
1:1477300:G:C	A78P	0.968

dbSNP variants (sampled 300 via entrez): RS1000000509 (1:1478185 A>T), RS1000060324 (1:1484097 A>C), RS1000185539 (1:1492755 T>G), RS1000195426 (1:1492903 C>T), RS1000305309 (1:1489526 A>C,G), RS1000387546 (1:1483300 C>G,T), RS1000404303 (1:1509494 T>G), RS1000521197 (1:1491848 T>A), RS1000555785 (1:1502213 T>C), RS1000735765 (1:1488913 C>G,T), RS1000802277 (1:1489645 C>T), RS1000834021 (1:1502502 C>A), RS1000882515 (1:1498574 C>G,T), RS1000922593 (1:1474420 G>A), RS1001060216 (1:1470109 T>G)

Disease associations

OMIM: gene MIM:612317 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005951_34	Body mass index	3.000000e-08
GCST010682_1	Graft survival time in renal transplantation (donor effect) x APOL1 genotype interaction	7.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0005199	renal transplant outcome measurement
EFO:0007892	donor genotype effect measurement
EFO:0009324	APOL1 risk genotype carrier status

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067438 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.73	Kd	18.59	nM	CHEMBL5653589
7.72	ED50	18.83	nM	CHEMBL5653589
7.10	Kd	79.89	nM	CHEMBL3752910
7.09	ED50	80.94	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147901: Binding affinity to human ATAD3B incubated for 45 mins by Kinobead based pull down assay	kd	0.0186	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147901: Binding affinity to human ATAD3B incubated for 45 mins by Kinobead based pull down assay	kd	0.0799	uM

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	4
bisphenol A	decreases expression, increases expression	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance	2
afuresertib	decreases expression	1
bisphenol F	increases expression	1
deoxynivalenol	increases expression	1
lead acetate	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
cupric chloride	increases expression	1
bisphenol B	increases expression	1
bisphenol S	increases expression	1
bisphenol AF	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arbutin	decreases expression	1
Clozapine	increases expression	1
Dinitrochlorobenzene	affects binding	1
Estradiol	increases expression	1
Ivermectin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Smoke	decreases expression	1
Thiram	increases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5650943	Binding	Binding affinity to human ATAD3B incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.